John M. Bedtelyon

Array ( [id] => 8126851 [patent_doc_number] => 20120087973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-12 [patent_title] => 'siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES' [patent_app_type] => utility [patent_app_number] => 13/069589 [patent_app_country] => US [patent_app_date] => 2011-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 16766 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0087/20120087973.pdf [firstpage_image] =>[orig_patent_app_number] => 13069589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9003186 [patent_doc_number] => 20130224311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-29 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 13/635893 [patent_app_country] => US [patent_app_date] => 2011-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 99 [patent_figures_cnt] => 99 [patent_no_of_words] => 44677 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13635893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8760096 [patent_doc_number] => 08420617 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-04-16 [patent_title] => 'Multiantivirus compound, composition and method for treatment of virus diseases' [patent_app_type] => utility [patent_app_number] => 13/046240 [patent_app_country] => US [patent_app_date] => 2011-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 15 [patent_no_of_words] => 20892 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13046240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8375325 [patent_doc_number] => 08258114 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-09-04 [patent_title] => 'Modulation of glucose-6-phosphatase translocase expression' [patent_app_type] => utility [patent_app_number] => 13/045187 [patent_app_country] => US [patent_app_date] => 2011-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37982 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13045187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10001673 [patent_doc_number] => 09045752 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'NKX3-1 saRNA and KLF4 saRNA and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/583905 [patent_app_country] => US [patent_app_date] => 2011-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 20 [patent_no_of_words] => 23864 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13583905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8964233 [patent_doc_number] => 20130203835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-08 [patent_title] => 'INHIBITORY RNAS TO RNA BINDING PROTEINS HNRNPA1, HNRNPA2 AND PTB AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/582921 [patent_app_country] => US [patent_app_date] => 2011-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 79 [patent_figures_cnt] => 79 [patent_no_of_words] => 23457 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13582921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8533379 [patent_doc_number] => 08309533 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-11-13 [patent_title] => 'Allele-specific RNA interference' [patent_app_type] => utility [patent_app_number] => 13/031534 [patent_app_country] => US [patent_app_date] => 2011-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 19 [patent_no_of_words] => 31435 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13031534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6188925 [patent_doc_number] => 20110171727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-14 [patent_title] => 'COMPOSITIONS AND METHODS FOR ACTIVATING GENES OF INTEREST' [patent_app_type] => utility [patent_app_number] => 13/026545 [patent_app_country] => US [patent_app_date] => 2011-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 6772 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0171/20110171727.pdf [firstpage_image] =>[orig_patent_app_number] => 13026545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6001807 [patent_doc_number] => 20110117646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-19 [patent_title] => 'ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION' [patent_app_type] => utility [patent_app_number] => 13/019190 [patent_app_country] => US [patent_app_date] => 2011-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25584 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0117/20110117646.pdf [firstpage_image] =>[orig_patent_app_number] => 13019190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8995018 [patent_doc_number] => 08518902 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-08-27 [patent_title] => 'Use of RNAi technology to inhibit ASIC3' [patent_app_type] => utility [patent_app_number] => 13/017738 [patent_app_country] => US [patent_app_date] => 2011-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 3 [patent_no_of_words] => 21542 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13017738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6178126 [patent_doc_number] => 20110178156 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-21 [patent_title] => 'Method of suppressing pRb deficiency-induced tumor formation' [patent_app_type] => utility [patent_app_number] => 12/930861 [patent_app_country] => US [patent_app_date] => 2011-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 9824 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0178/20110178156.pdf [firstpage_image] =>[orig_patent_app_number] => 12930861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6102706 [patent_doc_number] => 20110166199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-07 [patent_title] => 'RNAi COMPOUND TARGETED TO THROMBOSPONDIN-1 AND APPLICATIONS THEREOF' [patent_app_type] => utility [patent_app_number] => 12/985684 [patent_app_country] => US [patent_app_date] => 2011-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 3590 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20110166199.pdf [firstpage_image] =>[orig_patent_app_number] => 12985684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8490175 [patent_doc_number] => 20120289583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-15 [patent_title] => 'TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)' [patent_app_type] => utility [patent_app_number] => 13/519518 [patent_app_country] => US [patent_app_date] => 2010-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 25943 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13519518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8028303 [patent_doc_number] => 08143233 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-03-27 [patent_title] => 'RNA aptamers and methods for identifying the same' [patent_app_type] => utility [patent_app_number] => 12/971695 [patent_app_country] => US [patent_app_date] => 2010-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 45 [patent_no_of_words] => 31353 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/143/08143233.pdf [firstpage_image] =>[orig_patent_app_number] => 12971695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5973203 [patent_doc_number] => 20110152349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-23 [patent_title] => 'COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IL-18 GENES' [patent_app_type] => utility [patent_app_number] => 12/967432 [patent_app_country] => US [patent_app_date] => 2010-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 59 [patent_no_of_words] => 17819 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0152/20110152349.pdf [firstpage_image] =>[orig_patent_app_number] => 12967432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6186706 [patent_doc_number] => 20110124708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-26 [patent_title] => 'RNAI-MEDIATED INHIBITION OF OCULAR HYPERTENSION TARGETS' [patent_app_type] => utility [patent_app_number] => 12/967121 [patent_app_country] => US [patent_app_date] => 2010-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 19154 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0124/20110124708.pdf [firstpage_image] =>[orig_patent_app_number] => 12967121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8381455 [patent_doc_number] => 20120225088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-06 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING CANCER AND OTHER DISEASES' [patent_app_type] => utility [patent_app_number] => 13/510221 [patent_app_country] => US [patent_app_date] => 2010-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 17521 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13510221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9016506 [patent_doc_number] => 20130231470 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-05 [patent_title] => 'DEFIBROTIDE FOR USE IN PROPHYLAXIS AND/OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD)' [patent_app_type] => utility [patent_app_number] => 13/884102 [patent_app_country] => US [patent_app_date] => 2010-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4906 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8495498 [patent_doc_number] => 20120294905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-22 [patent_title] => 'Lipid Formulated Compositions And Methods For Inhibiting Expression Of Transthyretin (TTR)' [patent_app_type] => utility [patent_app_number] => 13/503843 [patent_app_country] => US [patent_app_date] => 2010-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 46797 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13503843 [rel_patent_id] =>[rel_patent_doc_number] =>)